Parexel Assigns Scott Smith As New Head Of Haematology

Scott Smith, M.D., Ph.D. has been named senior vice president, global therapeutic area head - haematology at Parexel, one of the world's largest CROs providing a full range of phase I to IV clinical development services. Dr. Smith will be responsible for leading Parexel's haematology therapeutic area and global team within our oncology centre of excellence in the development of new treatments for malignant haematology diseases as well as non-malignant haematology diseases.

"Cancer is expected to remain a significant healthcare burden in the future, making our medical expertise in this area even more critical to providing the support our customers and patients require to bring new, important therapies to market," said Amy McKee, M.D., chief medical officer and head of the oncology centre of excellence. "Dr. Scott's extensive knowledge in haematology, expertise in directing oncology clinical trials, and experience practising medicine make him the ideal choice to lead our haematology therapeutic area as we continue to strengthen Parexel's leadership position in this critical therapeutic area."

Dr. Smith is a licenced physician and surgeon at the Loyola University Medical Centre in Illinois with over 26 years of experience. Prior to joining Parexel, Scott worked at Loyola Medicine's Cardinal Bernardin Cancer Centre, where he held several positions of increasing responsibility, including director of the cancer clinical trials office, director of the bone marrow transplant programme, section chief of haematology, and associate director of clinical research. Dr. Smith made significant contributions to increasing the number of lymphoma clinical trials, assisting in the development of a new drug to treat relapsed Hodgkin's lymphoma while working to change the standard of care for patients. Dr. Smith has also served as executive officer for the Alliance of Clinical Trials in Oncology in Chicago, where he oversaw the group's haematology research portfolio.

He is active in the industry, serving on the SWOG Cancer Research Network's Lymphoma Committee, Bone Marrow and Stem Cell Transplant Committee, and the Protocol Review Committee at Loyola University Chicago. "At Parexel, we are passionate about achieving better outcomes for patients," said Peyton Howell, chief operating and growth officer. "By expanding our bench of medical experts and industry thought leaders, we continue to make progress in providing the best treatment options to patients around the world." Parexel is one of the world's largest clinical research organisations (CROs), offering a full range of clinical development services from phase I to IV to help life-saving treatments reach patients faster.